DK3681470T3 - Lactobacillus casei eller lactobacillus paracasei til anvendelse i behandling af clostridium difficile-infektioner - Google Patents
Lactobacillus casei eller lactobacillus paracasei til anvendelse i behandling af clostridium difficile-infektioner Download PDFInfo
- Publication number
- DK3681470T3 DK3681470T3 DK18773856.2T DK18773856T DK3681470T3 DK 3681470 T3 DK3681470 T3 DK 3681470T3 DK 18773856 T DK18773856 T DK 18773856T DK 3681470 T3 DK3681470 T3 DK 3681470T3
- Authority
- DK
- Denmark
- Prior art keywords
- lactobacillus
- treatment
- clostridium difficile
- difficile infections
- paracasei
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Dairy Products (AREA)
- Non-Alcoholic Beverages (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102017000101704A IT201700101704A1 (it) | 2017-09-12 | 2017-09-12 | Nuovo uso per trattamento delle infezioni da clostridium difficile |
| PCT/IB2018/056956 WO2019053604A1 (en) | 2017-09-12 | 2018-09-12 | NEW USE FOR THE TREATMENT OF DIFFICULT CLOSTRIDIUM INFECTIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3681470T3 true DK3681470T3 (da) | 2024-02-05 |
Family
ID=60991413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18773856.2T DK3681470T3 (da) | 2017-09-12 | 2018-09-12 | Lactobacillus casei eller lactobacillus paracasei til anvendelse i behandling af clostridium difficile-infektioner |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11338002B2 (da) |
| EP (1) | EP3681470B1 (da) |
| JP (2) | JP7387587B2 (da) |
| KR (1) | KR102713227B1 (da) |
| CN (1) | CN111246839B (da) |
| AU (1) | AU2018333114B2 (da) |
| BR (1) | BR112020004780A2 (da) |
| CA (1) | CA3075235A1 (da) |
| DK (1) | DK3681470T3 (da) |
| ES (1) | ES2969690T3 (da) |
| IT (1) | IT201700101704A1 (da) |
| MX (1) | MX2020002727A (da) |
| PL (1) | PL3681470T3 (da) |
| RU (1) | RU2020112241A (da) |
| WO (1) | WO2019053604A1 (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20131467A1 (it) | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
| MA39710A (fr) | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
| ITUA20164188A1 (it) | 2016-06-08 | 2017-12-08 | Sofar Spa | Nuovo uso medico di probiotici |
| IT201600122724A1 (it) | 2016-12-02 | 2018-06-02 | Sofar Spa | Exopolysaccharides and uses thereof |
| IT201600127498A1 (it) | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
| EP3860457A1 (en) * | 2018-10-06 | 2021-08-11 | The Cleveland Clinic Foundation | Method for diagnosing clostridioides difficile infection |
| CA3113221A1 (en) * | 2018-10-10 | 2020-04-16 | Nutri Co., Ltd. | Preventive and/or therapeutic agent for clostridium difficile infection |
| AU2020287268B2 (en) * | 2019-06-05 | 2026-02-19 | Lac2biome S.r.l. | Compositions comprising a bacterial strain lactobacillus paracasei and hyaluronic acid and the use thereof for the treatment of the skin |
| IT201900016865A1 (it) * | 2019-09-20 | 2021-03-20 | Sofar Spa | Composizioni a base di ceppi batterici e loro uso come antinfiammatori |
| WO2021081362A1 (en) * | 2019-10-25 | 2021-04-29 | Newgen 27, Llc | Synbiotic compositions for gut microbiota |
| JP7362417B2 (ja) * | 2019-10-25 | 2023-10-17 | ライオン株式会社 | 口腔内病原性細菌の生育抑制剤、口腔用組成物及び促進剤 |
| US11751597B2 (en) | 2019-11-05 | 2023-09-12 | Alfasigma S.P.A. | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems |
| CN112442472B (zh) * | 2020-11-30 | 2023-05-26 | 四川大学华西医院 | 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法 |
| CN112322553B (zh) * | 2020-11-30 | 2022-09-27 | 四川大学华西医院 | 一种抗艰难梭菌的乳酸乳球菌及其应用 |
| CN112625983B (zh) * | 2021-03-05 | 2021-05-28 | 山东中科嘉亿生物工程有限公司 | 一种对腹泻有治疗效果的干酪乳杆菌L.Casei21及其应用 |
| WO2023287025A1 (ko) * | 2021-07-12 | 2023-01-19 | 한국생명공학연구원 | 큐티박테리움 아비덤 균주, 그의 유래의 배양액 및 그의 항균 용도 |
| KR102701916B1 (ko) * | 2021-07-12 | 2024-09-04 | 한국생명공학연구원 | 큐티박테리움 아비덤 균주, 그의 유래의 배양액 및 그의 항균 용도 |
| KR102391832B1 (ko) * | 2021-08-04 | 2022-04-28 | 한국식품연구원 | 클로스트리디오이데스 디피실 억제용 유산균 복합 균주 및 이를 포함하는 장염증 예방, 치료 또는 개선용 조성물 |
| KR102452957B1 (ko) * | 2022-03-14 | 2022-10-11 | 한동대학교 산학협력단 | 프로바이오틱스 균주를 유효성분으로 포함하는 클로스트리디오이데스 디피실레 감염을 예방 또는 치료하기 위한 조성물 |
| KR102539776B1 (ko) * | 2022-11-14 | 2023-06-07 | 주식회사 바이오뱅크힐링 | 홀데마넬라 바이포미스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102539772B1 (ko) * | 2022-11-14 | 2023-06-07 | 주식회사 바이오뱅크힐링 | 락토코커스 락티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102539773B1 (ko) * | 2022-11-14 | 2023-06-07 | 주식회사 바이오뱅크힐링 | 루미노코커스 락타리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| CN116004483B (zh) * | 2023-03-09 | 2023-06-02 | 四川厌氧生物科技有限责任公司 | 一种预防或治疗腹泻的格氏乳球菌及其应用 |
| KR102620187B1 (ko) * | 2023-08-08 | 2024-01-04 | 주식회사 바이오뱅크힐링 | 리길락토바실러스 루미니스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도 |
| KR102628941B1 (ko) * | 2023-08-08 | 2024-01-26 | 주식회사 바이오뱅크힐링 | 프레보텔라 코프리 균주, 및 그의 유래의 소포체 및그의 항염증 및 항균 용도 |
| WO2025033636A1 (ko) * | 2023-08-08 | 2025-02-13 | 주식회사 바이오뱅크힐링 | 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102620188B1 (ko) * | 2023-08-08 | 2024-01-04 | 주식회사 바이오뱅크힐링 | 락티카제이바실러스 지애 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도 |
| WO2025033635A1 (ko) * | 2023-08-08 | 2025-02-13 | 주식회사 바이오뱅크힐링 | 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102620185B1 (ko) * | 2023-08-08 | 2024-01-04 | 주식회사 바이오뱅크힐링 | 블라우티아 호미니스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도 |
| CN119506119A (zh) * | 2024-09-05 | 2025-02-25 | 重庆医科大学 | 一株副干酪乳杆菌w1及其在抑制艰难拟梭菌感染中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20030283A1 (es) * | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
| CA2470090A1 (fr) * | 2004-06-18 | 2005-12-18 | Bio-K Plus International Inc. | Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques |
| EP2672980B1 (en) * | 2011-02-09 | 2017-12-06 | Lavivo AB | Synbiotic compositions for restoration and reconstitution of gut microbiota |
| ITMI20131467A1 (it) * | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
| ITMI20131473A1 (it) * | 2013-09-06 | 2015-03-07 | Sofar Spa | Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale |
| MA39710A (fr) * | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
-
2017
- 2017-09-12 IT IT102017000101704A patent/IT201700101704A1/it unknown
-
2018
- 2018-09-12 BR BR112020004780-5A patent/BR112020004780A2/pt unknown
- 2018-09-12 EP EP18773856.2A patent/EP3681470B1/en active Active
- 2018-09-12 JP JP2020514676A patent/JP7387587B2/ja active Active
- 2018-09-12 ES ES18773856T patent/ES2969690T3/es active Active
- 2018-09-12 RU RU2020112241A patent/RU2020112241A/ru unknown
- 2018-09-12 KR KR1020207010497A patent/KR102713227B1/ko active Active
- 2018-09-12 DK DK18773856.2T patent/DK3681470T3/da active
- 2018-09-12 MX MX2020002727A patent/MX2020002727A/es unknown
- 2018-09-12 PL PL18773856.2T patent/PL3681470T3/pl unknown
- 2018-09-12 WO PCT/IB2018/056956 patent/WO2019053604A1/en not_active Ceased
- 2018-09-12 AU AU2018333114A patent/AU2018333114B2/en active Active
- 2018-09-12 US US16/642,337 patent/US11338002B2/en active Active
- 2018-09-12 CA CA3075235A patent/CA3075235A1/en active Pending
- 2018-09-12 CN CN201880059030.6A patent/CN111246839B/zh active Active
-
2023
- 2023-11-14 JP JP2023193960A patent/JP7801294B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020112241A3 (da) | 2021-11-12 |
| JP2024003162A (ja) | 2024-01-11 |
| CN111246839B (zh) | 2023-11-21 |
| AU2018333114B2 (en) | 2024-11-07 |
| EP3681470A1 (en) | 2020-07-22 |
| JP7387587B2 (ja) | 2023-11-28 |
| PL3681470T3 (pl) | 2024-04-02 |
| CA3075235A1 (en) | 2019-03-21 |
| IT201700101704A1 (it) | 2019-03-12 |
| ES2969690T3 (es) | 2024-05-22 |
| WO2019053604A1 (en) | 2019-03-21 |
| CN111246839A (zh) | 2020-06-05 |
| AU2018333114A1 (en) | 2020-04-09 |
| BR112020004780A2 (pt) | 2020-09-24 |
| EP3681470B1 (en) | 2023-11-08 |
| JP2020533351A (ja) | 2020-11-19 |
| US11338002B2 (en) | 2022-05-24 |
| US20200306323A1 (en) | 2020-10-01 |
| KR20200065004A (ko) | 2020-06-08 |
| RU2020112241A (ru) | 2021-10-18 |
| KR102713227B1 (ko) | 2024-10-02 |
| JP7801294B2 (ja) | 2026-01-16 |
| MX2020002727A (es) | 2020-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3681470T3 (da) | Lactobacillus casei eller lactobacillus paracasei til anvendelse i behandling af clostridium difficile-infektioner | |
| DK3490582T3 (da) | Sammensætninger til anvendelse i behandling af myelofibrose | |
| PL3386534T3 (pl) | Kompozycje i sposoby internalizacji enzymów | |
| DK3528825T3 (da) | Fremgangsmåder og sammensætninger til ændring af sammensætningen af hudmikrobiomet under anvendelse af komplekse blandinger af bakteriestammer | |
| DK3528838T3 (da) | Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis | |
| DK3310917T3 (da) | Hidtil ukendte crispr-enzymer og -systemer | |
| DK3212208T3 (da) | Anvendelse af l. reuteri til forebyggelse eller behandling af mikrobiotadysbiose tidligt i livet | |
| SG11201707683YA (en) | C/ebp alpha sarna compositions and methods of use | |
| HUE15821025T1 (hu) | Rekombináns probiotikus baktérium | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| EP3134409A4 (en) | Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | |
| DK3641753T3 (da) | Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner | |
| DK3442547T3 (da) | Lactobacillus reuteri MM4-1A til anvendelse i behandling eller forebyggelse af autismespektrumforstyrrelser | |
| DK3247352T3 (da) | Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion | |
| DK3484585T3 (da) | Anvendelse af probiotika ved behandling og/eller forebyggelse af atopisk dermatitis | |
| DK3387156T3 (da) | Lactobacillus casei til behandling af fedme og associerede metabolske sygdomme | |
| DK3259515T3 (da) | Fitting med coating, rørledningssystem og anvendelse af fittingen eller rørledningssystemet | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose | |
| IL257684A (en) | A bacterium for milk fermentation that lowers the concentration of acetaldehyde | |
| IL274291A (en) | Compounds and their use in the proliferation of stem cells and/or progenitor cells | |
| PT3393485T (pt) | Composições probióticas e uso das mesmas | |
| EP3651783C0 (en) | NEW COMPOSITION OF PROBIOTICS FOR THE PREVENTION OF BACTERIAL VAGINOSIS | |
| DK3541961T3 (da) | Streptococcus thermophilus til anvendelse i fremstilling af fermenterede produkter | |
| EP3511409A4 (en) | SALT-TOLERANT LACTOBACILLA, SALT-TOLERANT LACTOBACIL CULTURE AND IMMUNOSTIMULATOR | |
| IL250554A0 (en) | Improved substrates that promote bone growth and methods of making them |